CD274 and neoplasm: Certain predictive biomarkers for the response to ICB have been identified, such as PD-L1 expression17, tumor mutation burden (TMB)18, mismatch repair deficiency (dMMR) or microsatellite instability (MSI)19, and tumor-infiltrating lymphocyte (TIL) levels20.